Hostname: page-component-76fb5796d-wq484 Total loading time: 0 Render date: 2024-04-26T01:39:04.973Z Has data issue: false hasContentIssue false
  • English
  • Français

Antipsychotic drugs: atypical advantages and typical disadvantages

Published online by Cambridge University Press:  13 June 2014

Padraig Wright  and
Luke O'Flaherty
Padraig Wright
Affiliation:
St. Brendan's Hospital, PO Box 418, Rathdown Road, Dublin 7, Ireland and Senior Lecturer (Honorary), Institute of Psychiatry, London, England
Luke O'Flaherty
Affiliation:
St Brendan's Hospital, Rathdown Road, Dublin 7, Ireland
Get access Rights & Permissions [Opens in a new window]

Extract

Atypical antipsychotic drugs are recommended for the first line treatment of all patients with schizophrenia. This is because it has been demonstrated that atypical antipsychotic drugs are more effective across a broader range of symptoms of schizophrenia than typical antipsychotic drugs and because they are dramatically less likely to cause the extrapyramidal and endocrine side effects that greatly impair quality of life for patients and reduce their willingness to adhere to maintenance treatment. Atypical antipsychotic drugs are not perfect but they are the most effective and the safest treatment for schizophrenia presently available.

The atypical antipsychotic drugs currently marketed in Ireland for the first line treatment of schizophrenia include amisulpride, olanzapine, quetiapine, risperidone and ziprasidone. These agents differ somewhat in chemical class, indications, daily dose range, need for titration, daily dosing regimen and available formulations (see Table 1). Clozapine is marketed for patients unresponsive to, or intolerant of, other antipsychotic drugs and must thus be regarded as a second line treatment for schizophrenia. Zotepine is not yet available in Ireland while the marketing of sertindole has been suspended following reports of arrhythmias and sudden cardiac deaths.

Type
Perspective
Information
Irish Journal of Psychological Medicine , Volume 20 , Issue 1 , March 2003 , pp. 24 - 27
Copyright
Copyright © Cambridge University Press 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. National Institute for Clinical Excellence. Technology appraisal guidance No. 43. Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. NICE, London, June 2002.Google Scholar
2. Monthly Index of Medical Specialities (Ireland) June 2002. Medical Publications Ireland Ltd.Google Scholar
3.Petty, RG. Prolactin and antipsychotic medications: mechanism of action. Schiz Res 2000; 35, S67–S73.CrossRefGoogle Scholar
4.Andreasen, NC, Olsen, 5. Negative v positive schizophrenia. Am J Psychiatry 1982; 39, 789–94.Google Scholar
5.Tran, PV, Hamilton, SH, Kuntz, AJ, Potvin, JH, Andersen, SW, Beasley, C Jr, Tollefson, GD. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997, 17(5): 407–18.CrossRefGoogle ScholarPubMed
6.Censits, DM, Ragland, JO, Gur, RC, Gur, RE. Neuropsychological evidence supporting a neurodevelopmental model of schizophrenia: a longitudnal study. Schizophrenia Research 1997; 24: 289–98.CrossRefGoogle Scholar
7.Purdon, SECognitive improvement in schizophrenia with novel antipsychotic medications. Schizophr Res 1999 Mar 1;35 Suppl:S51-60.CrossRefGoogle ScholarPubMed
8.Rosenheck, R, Cramer, J, Xu, W, Thomas, J, Henderson, W, Frisman, L, Fye, C, Charney, D. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Croup on Clozapine in Refractory Schizophrenia. N Eng/JMed 1997 Sep 18; 337(12): 809–15.CrossRefGoogle Scholar
9.Moller, HJ, Boyer, P, Fleurot, O, Rein, W. Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group. Psychopharmacology (Ben) 1997 Aug; 132(4): 396–401.Google ScholarPubMed
10.Tollefson, GD, Beasley, CM Jr, Tran, PV, Street, JS, Krueger, JA, Tamura, RN, Graffeo, KA, Thieme, MEOlanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997a Apr; 154(4): 457–65.Google ScholarPubMed
11.Arvanitis, LA, Miller, BGMultiple fixed doses of ‘Seroquel’ (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997 Aug 15; 42(4): 233–46.CrossRefGoogle ScholarPubMed
12.Peuskens, J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry 1995 Jun; 166(6): 712–26.CrossRefGoogle ScholarPubMed
13.Daniel, DG, Zimbroff, DL, Potkin, SG, Reeves, KR, Harrigan, EP, Lakshminarayanan, M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 1999 May;20(5):491–505.CrossRefGoogle ScholarPubMed
13a. Pfizer Inc. briefing document, FDA Psychopharmacology Drugs Advisory Committee, July 19th 2000 (www.fda.giv/ohrms/dockets/ac/00/backgrd/3619b1a.pdf)Google Scholar
13b.Maudsley, H. The pathology of mind. 3rd Ed. Macmillan, London, 1879Google Scholar
13c.Braceland, FJ, Meduna, U, Vaichulis, JA. Delayed action of insulin in schizophrenia. Am J Psychiatry 1945: 102, 108–110.CrossRefGoogle Scholar
13d.Charatan, FBE, Bartlett, NG. 1955. The effect of chlorpromazine (‘Largactil’) on glucose tolerance. J Ment Sci 101: 351–3.CrossRefGoogle ScholarPubMed
13e.Erie, G, Basso, M, Federspil, G, Sicolo, N, Scandellan, C. 1977. Effect of chlorpromazine on blood glucose and plasma insulin in man. Eur J Clin Pharmacol 11 (1):15–18.Google Scholar
13f.Freeman, H. 1946. Resistance to insulin in mentally disturbed soldiers. Arch Neurol Psychiatry 56: 74–8.CrossRefGoogle ScholarPubMed
13g.Langfeldt, G. The insulin tolerance test in mental disorders. Acta psychiatr Scand 1952; 80 (Suppl) 189–200.Google ScholarPubMed
13h.Lorenz, WF. Sugar tolerance in dementia praecox and other mental disorders. Arch Neurol Psychiatry 1922; 184–96.CrossRefGoogle Scholar
13i.Thonnard-Neumann, E. 1968. Phenothiazines and diabetes in hospitalized women. Am J Psychiatry 124:138–142.CrossRefGoogle ScholarPubMed
13j.Koller, E, Schneider, B, Bennett, K, Dubitsky, G. Clozapine-associated diabetes. Am J Med 2001 Dec 15; 111 (9): 716–23.CrossRefGoogle ScholarPubMed
13k.Koller, EA, Doraiswamy, PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy 2002 Jul; 22(7): 841–52.CrossRefGoogle ScholarPubMed
13l.Koller, EA, P Murali, Doraiswamy, James T, Cross. Risperidone-Associated Diabetes. Div of Metabolic and Endocrine Drug Products, Food and Drug Administration, Rockville, MD; Dept of Psychiatry and Behavioral Scis, Duke Univ Med Ctr, Durham, NCGoogle Scholar
14.Kane, J, Honigfeld, G, Singer, J, Meltzer, H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988 Sep; 45(9): 789–96.CrossRefGoogle ScholarPubMed
15.Chouinard, C, Jones, B, Remington, Cet al.A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Int Psychopharmacol 1993 Feb; 13(1): 25–40.Google ScholarPubMed
16.Sanger, TM, Lieberman, JA, Tohen, M, Grundy, S, Beasley, C Jr, Tollefson, GD. Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry 1999 Jan; 156: 79–87.CrossRefGoogle ScholarPubMed
17.Hirsch, SR, Jolley, AG (1989) The dysphoric syndrome in schizophrenia and its implications for relapse. Br J Psych 155, Suppl 5, 46–50.CrossRefGoogle Scholar
18.Fenton, WS, McGlashan, TH, Victor, BJet al.Symptoms, subtype and suicidality in patients with schizophrenia spectrum disorder. Am J Psych 1997; 154, 199–204.Google Scholar
19.Peuskens, J, Bech, PMoller, NJet al.Amisulpride versus risperidone in the treatment of acute exacerbations of schizophrenia. Psychiatry Research 1999; 88, 107–17.CrossRefGoogle Scholar
20.Purdon, SE, Jones, BD, Stip, Fet al.Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry 2000, 57(3): 249–58.CrossRefGoogle ScholarPubMed
21.Remington, G, Kapur, S. Atypical antipsychotics: are some more atypical than others? Psychopharmacology (Berl) 2000 Jan; 148(1): 3–15.CrossRefGoogle ScholarPubMed
22.Hoge, SK, Appelbaum, PS, Lawlor, Tet al.A prospective, multicenter study of patients' refusal of antipsychotic medication. Arch Gen Psychiatry 1990 Oct;47(10): 949–56.CrossRefGoogle ScholarPubMed
23.Tollefson, GD, Beasley, CM Jr, Tamura, RN, Tran, PV, Potvin, JH. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 1997 Sep;154(9): 1248–54.Google ScholarPubMed
24.Lemmens, P, Brecher, M, Van Baelen, B. A combined analysis of double-blind studies with risperidone vs. placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms. Acta Psychiatr Scand 1999 Mar;99(3):160–70.CrossRefGoogle ScholarPubMed
25.Gerlach, J, Peacock, L. Motor and mental side effects of clozapine. J Clin Psychiatry 1994 Sep;55 Suppl B:107–9.Google ScholarPubMed
26.O'Hara, P, Brugha, TS, Lesage, A, Wing, J. New findings on tardive dyskinesia in a community sample. Psychol Med 1993 May; 23(2): 453–65.CrossRefGoogle Scholar
27.Pickar, D, Owen, RR, Litman, RE, Konicki, E, Gutierrez, R, Rapaport, MH. Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine. Arch Gen Psychiatry 1992 May; 49(5): 345–53.CrossRefGoogle ScholarPubMed
28.Coulouvrat, C, Dondey-Nouvel, L. Safety of amisulpride (Solian): a review of 11 clinical studies. Int Clin Psychopharmacol 1999 Jul; 14(4): 209–18.CrossRefGoogle ScholarPubMed
29.Claus, A, Bollen, J, De Cuyper, Het al.Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 1992 Apr; 85(4): 295–305.CrossRefGoogle ScholarPubMed
30.Allison, DB, Mentore, JL, Fleo, Met al.Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156, 1686–96.CrossRefGoogle Scholar
31.Warner, et al.Electrocardiographic changes in patients receiving neuroleptic medication. Acta Psychiatr Scand 1996; 93: 311–3.CrossRefGoogle ScholarPubMed
32.Reilly, et al.QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000; 355: 1048–52.CrossRefGoogle ScholarPubMed
33.Wright, P. Schizophrenia and related disorders. In: Core Psychiatry (Eds. Wright, P, Stern, J, Phelan, M) London: Saunders; 2000, 259–92.Google Scholar